Modern approaches to the treatment and prevention of fungal urinary tract infections

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Studies in recent years show an increase in the incidence of fungal urinary tract infection (UTI). The most common causative agents of fungal UTIs are representatives of the genus Candida. Antifungal therapy is indicated in case of the detection of fungi in the urine of patients with symptoms of UTI, immunocompromised patients, low birth weight newborns, and also before urological surgical interventions. For the treatment of urinary tract candidiasis, the use of drugs of the triazole group - amphotericin B and flucytosine is recommended. Fluconazole is the most common drug for treating fungal urinary tract infections. Unlike other azoles, fluconazole is available for oral administration, soluble in water, up to 80% of the drug is excreted unchanged by the kidneys, creating an effective concentration in the urine. The frequency of fluconazole-sensitive strains of fungal UTI pathogens is gradually decreasing. Therapy with fluconazole for fungal UTIs is recommended for 7-14 days. Prevention of fungal UTI in most cases does not require drug therapy. The basis for the prevention of the development of fungal UTI includes the correction of risk factors for the development of this disease: the timely removal or replacement of urinary drainage, the cessation of antibiotic therapy and the restoration of the passage of urine through the urinary tract.

Full Text

Restricted Access

About the authors

N. V Sturov

RUDN University

Department of General Medical Practice, Medical Institute Moscow, Russia

S. V Popov

RUDN University

Email: popov-serv@rudn.ru
Department of General Medical Practice, Medical Institute Moscow, Russia

I. Yu Shmelkov

RUDN University

Department of General Medical Practice, Medical Institute Moscow, Russia

References

  1. Rishpana M, Kabbin J. Candiduria in Catheter Associated Urinary Tract Infection with Special Reference to Biofilm Production. J Clin Diagnost Res. 2015;9(10):DC11-3. Doi: 10.7860/ JCDR/2015/13910.6690.
  2. Sohail M, Khurshid M., Saleem H., et al. Characteristics and Antibiotic Resistance of Urinary Tract Pathogens Isolated From Punjab, Pakistan. Jundish. J Microbiol. 2015;8(7):e19272. doi: 10.5812/jjm.19272v2.
  3. Alfouzan W.A. Candiduria: Evidence-based approach to management, are we there yet? J Mycol Med. 2017;27(3):293-302. doi: 10.1016/j.mycmed.2017.04.005.
  4. Gharanfoli A., Mahmoudi E., Torabizadeh R., et al. Isolation, characterization, and molecular identification of Candida species from urinary tract infections. Curr Med Mycol. 2019;5(2):33-6. doi: 10.18502/cmm.5.2.1159.
  5. Suzuki M., Hiramatsu M., Fukazawa M., et al. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans. Diab Obes Metab. 2014;16(7):622-27. doi: 10.1111/dom.12259.
  6. Peman A.Ruiz-Gaitan Candidemia from urinary tract source: the challenge of candiduria. Hospital Pract. 2018;46(5):243-45. doi: 10.1080/21548331.2018.1538623.
  7. Raman N, Lee M., Rodriguez Lopez A., et al. Antifungal Activity of a в-Peptide in Synthetic Urine Media: Toward Materials-Based Approaches to Reducing Catheter-Associated Urinary Tract Fungal Infections. Acta Biomater. 2016;43:240-doi: 10.1016/j.actbio.2016.07.016.
  8. Gajdacs M., Doczi I., Abrok M., et al. Epidemiology of candiduria and Candida urinary tract infections in inpatients and outpatients: results from a 10-year retrospective survey. Cent Eur J Urol. 2019;72:2 09-14. Doi: 10.5173/ ceju.2019.1909.
  9. Li Z, Wen J., Zhang N., et al. Emphysematous prostatic abscess due to candidiasis: A case report and review of the literature. Med. 2020;99(9): e19391. Doi: 10.1097/ MD.0000000000019391.
  10. Behzadi P, Behzadi E., Ranjbar P Urinary tract infections and Candida albicans. Cent Eur J Urol. 2015;68:96-101. Doi: 10.5173/ ceju.2015.01.474.
  11. Datta P, Kaur M., Chander J. Epidemiology and Antifungal Susceptibility of Candida Species Isolated from Urinary Tract Infections: A Study from an Intensive Care Unit of a Tertiary Care Hospital. Indian J Crit Care Med. 2018;22(1):56-doi: 10.4103/ijccm.IJCCM_130_17.
  12. OdabasiZ., Mert A. Candida urinary tract infections in adults. W J Urol. 2020;38(11):2699-707. doi: 10.1007/s00345-019-02991-5.
  13. Toner L., Papa N., Aliyu S., et al. Candida growth in urine cultures: a contemporary analysis of species and antifungal susceptibility profiles. An Int J Med. 2016;10:325-29. doi: 10.1093/qjmed/ hcv202.
  14. Ozer T., Durmaz S., Yula Ozer E. Antifungal susceptibilities of Candida species isolated from urine culture. J Infect Chemother. 2016;9:629-doi: 10.1016/j.jiac.2016.06.012.
  15. Benjamin M.D., Jolivet E., Desbois N., et al. Fungal colonization in preterm neonates weighing less than 1500g admitted to the neonatal intensive care unit. Arch Pediatr. 2016;23(9):887-94. doi: 10.1016/j.arcped.2016.05.018.
  16. Jacobs D., Dilworth T., Beyda N., et al. Overtreatment of Asymptomatic Candiduria among Hospitalized Patients: a Multi-institutional Study. Antimicrob. Agent. Chemother. 2017;62(1):e01464-17. Doi: 10.1128/ AAC.01464-17.
  17. Pappas P, Kauffman C., Andes D., et al. Clinical Practice Guidelines for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Inf Dis. 2016;62:e1-50. doi: 10.1093/cid/civ933.
  18. Климко Н.Н. Диагностика и лечение микозов в отделениях реанимации и интенсивной терапии: Российские рекомендации. М., 2015. 96 с.
  19. Fisher J., Sobel J., Kauffman C., et al. Candida Urinary Tract Infections - Treatment. Clin Inect Dis. 2011;52(6):S457-66. doi: 10.1093/cid/ cir112.
  20. Sutcu M., Acar M., Genc G., et al. Evaluation of Candida species and antifungal susceptibilities among children with invasive candidiasis. Turk Pediatri Ars. 2017;52:145-53. Doi: 10.5152/ TurkPediatriArs.2017.5291.
  21. Gubbins P.O., McConnell S.A., Penzak S.R. Current management of funguria. Am J Health-Syst Pharm. 1999;56:1929-35.
  22. Wang Q., Li C., Tang D., et al. Molecular epidemiology of Candida tropicalis isolated from urogenital tract infections. Microbiologyopen. 2020;9:e1121. doi: 10.1002/mbo3.1121.
  23. Wu Y., Wu M., Wang Y., et al. ERG11couples oxidative stress adaptation, hyphalelongation and virulence in Candida albicans. FEMS Yeast Res. 2018;18(7):1-7. doi: 10.1093/femsyr/foy057.
  24. Chaari A., Ismail M., Abdel Hakim K., et al. Effectiveness of Systemic Fluconazole in Adult Patients With Asymptomatic Candiduria: A Systematic Review and Meta-Analysis. Am J Ther. 2017;24(6):e758-62. Doi: 10.1097/ MJT.0000000000000403.
  25. Ding R., Li X., Zhang X., et al. The Epidemiology of Symptomatic Catheter-associated Urinary Tract Infections in the Intensive Care Unit: A 4-year Single Center Retrospective Study. Miscellaneous. 2019;16(03):312-17. Doi: 10.22037/ uj.v0i0.4256.
  26. FDA Approved Drug Products Diflucan (fluconazole) [Electronic resource]. - Pfizer.: Roerig division of Pfizer corp., 2019. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019949s065,020090s047lbl.pdf.
  27. Cho-Han C., Sung-Ching P., Tyan-Shin Y., et al. Healthcare-associated infections in intensive care units in Taiwan, South Korea, and Japan: recent trends based on national surveillance reports. Antimicrob Resist Inf Control. 2018;7:129. doi: 10.1186/s13756-018-0422-1.
  28. Lima G., Nunes M., Chang M., et al. Identification and antifungal susceptibility of Candida species isolated from the urine of patients in a university hospital in Brazil. Rev Inst Med Trop S o Paulo. 2017;59:e75-83. doi: 10.1590/S1678-9946201759075.
  29. Maskarineca S., Parlakb Z., Tub Q., et al. On-demand release of Candida albicans biofilms from urinary catheters by mechanical surface deformation. Biofouling. 2018;34(6):595-604. doi: 10.1080/08927014.2018.1474461.
  30. Веселов А.В. In vitro активность флуконазола и вориконазола в отношении более 10000 штаммов дрожжей: результаты 5-летнего проспективного исследования ARTEMIS Disk в России. Клиническая микробиология и антимикробная химиотерапия. 2008;4:345-54. [Veselov A.V. In vitro activity of fluconazole and voriconazole against more than 10,000 yeast strains: results of a 5-year prospective study ARTEMIS Disk in Russia. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2008;4:345-54. (In Russ.)].
  31. Lai C., Lee C., Chiang H., et al. Implementation of a national bundle care program to reduce catheter-associated urinary tract infection in high-risk units of hospitals in Taiwan. J Microbiol. Immunol Infect. 2017;50:464-70. Doi: 10.1016/j. jmii.2017.01.006.
  32. Padda I., Parmar M. Flucytosine. StatPearls. 2020; URL: https://www.ncbi.nlm.nih.gov/books/NBK557607.
  33. Liu Y., Xiao D., Xiao-hui S. Urinary tract infection control in intensive care patients. Med. 2018;97:38-40. Doi: 10.1097/ MD.0000000000012195.
  34. Van Dijck P., Sjollema J., Cammue B. Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial. Cell. 2018;5(7):300-26. Doi: 10.15698/ mic2018.07.638.
  35. Sullivan K, Caylor M., Lin F, et al.Comparison of Amphotericin B BladderIrrigations Versus Fluconazole for the Treatment of Candiduria in Intensive Care Unit Patients. Pharm Pract. 2017;30(3):347-52. doi: 10.1177/0897190016645032.
  36. Lundstrom T, Sobel J. Nosocomial Candiduria: A Review. Clin Infect Dis. 2001;32:1602-7. doi: 10.1086/320531.
  37. Караев З.О. Нозокомиальные микозы: состояние и перспективы решения проблемы. Проблемы медицинской микологии. 2007;9:21-3. [Karaev Z.O. Nosocomial mycoses: state and prospects for solving the problem. Problemy Meditsinskoi Mykologii. 2007;9:21-3. (In Russ.)].
  38. Cuervo G., Garcia-Vidal C., Puig-Asensio M., et al. Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. Clin Infect Dis. 2017;64(10):1374-79. doi: 10.1093/cid/ cix033.
  39. Gabardi S., Martin S., Sura M., et al. Micafungin treatment and eradication of candiduri0a among hospitalized patients.Int Urol Nephrol. 2016;48(11):1881-85. doi: 10.1007/s11255-016-1410-0.
  40. Garcia H., Guitard J., Peltier J., et al. Caspofungin irrigation through percutaneous calicostomy catheter combined with oral flucytosine to treat fluconazole-resistant symptomatic candiduria. J Mycol Med. 2015;25(1):87-90. Doi: 10.1016/j. mycmed.2014.12.003.
  41. Edward E.A., Mohamed N.M., Zakaria A.S. Resensitization of Fluconazole-Resistant Urinary Candida spp. Isolates by Amikacin through Downregulation of Efflux Pump. Gen. Polish J Microbiol. 2020;69(1):73-84. Doi: 10.33073/ pjm-2020-010.
  42. Hof H. Candiduria! What now? Therapy of urinary tract infections with Candida. Urol. 2017;56(2):172-79. doi: 10.1007/s00120-016-0219-x.
  43. Saag M., Graybill R., Larsen R., et al. IDSA practice guidelines for the management of cryptococcal disease. Clin Inf Dis. 2000;30:710-18. doi: 10.1086/313757.
  44. Pouladfar G., Jafarpour Z., Firoozifar M., et al. Urinary Tract Infections Among Hospitalized Adults in the Early Post-Liver Transplant Period: Prevalence, Risk Factors, Causative Agents, and Microbial Susceptibility. Exp Clin Transplantat. 2017;15(1):190-93. doi: 10.6002/ect. mesot2016.P68.
  45. Rahimkhani M., Saberian M., Mordadi A., et al. Urinary Tract Infection with Candida glabrata in a Patient with Spinal Cord Injury. Acta Med Iranica. 2015;53(8):516-17.
  46. Huang S., Septimus E., Hayden M., et al. Effect of body surface decolonisation on bacteriuria and candiduria in intensive care units: an analysis of a cluster-randomised trial [Electronic resource]. Lancet. Inf Dis. 2016;16(1):70-9. URL: https://escholarship.org/uc/item/6kc6f7b6. doi: 10.1016/S1473-3099(15)00238-8.
  47. Nair S., Baranwal G., Chatterjee M., et al. Antimicrobial activity of plumbagin, a naturally occurring naphthoquinone from Plumbago rosea, against Staphylococcus aureus and Candida albicans.Int J Microbiol. 2016;4:237-48. doi: 10.1016/j.ijmm.2016.05.004.
  48. Sundararajan A., Rane H., Ramaraj T., et al. Cranberry-derived proanthocyanidins induce a differential transcriptomic response within Candida albicans urinary biofilms. PLoS ONE. 2018;13(8):e0201969. doi: 10.1371/journal. pone.0201969.
  49. Hosseini S., Ghaemi E., Noroozi A., et al. Zinc Oxide Nanoparticles Inhibition of Initial Adhesion and ALS1 and ALS3 Gene Expression in Candida albicans Strains from Urinary Tract Infections. Mycopathol. 2019;184(2):261-71. doi: 10.1007/s11046-019-00327-w.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies